Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Summit Therapeutics Inc (SMMT) vs Visa Inc (V) Price & Performance

Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Summit Therapeutics Inc vs Visa Inc — how do they compare? Summit Therapeutics Inc trades at $15.3 (market cap $12.06B), while Visa Inc trades at $358.73 (market cap $671.74B). The key difference: Visa Inc is far larger — about 55.7× Summit Therapeutics Inc's market cap, and Visa Inc pays a 0.74% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.

SMMTV
Market Cap
$12.06B$671.74B
Sector
HealthFinancials
52-Week High
$26.98$370.47
52-Week Low
$12.55$295.52
Enterprise Value
$11.39B$682.32B
Volume
10,431,336
Dividend Yield
0.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.

Visa Inc

Visa (V) trades at $361.32, down 0.33% on the day, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $3.32 exceeding the $3.23 estimate. Revenue grew to $40 billion in 2025, with a net income margin of 50.78%. Recent news highlights Visa's AI initiatives, such as Intelligent Commerce Connect, to enhance payment efficiency.

The outlook remains positive due to high analyst buy ratings (85.48%) and a consensus price target of $426.31, implying 18% upside. Risks include fintech competition and regulatory pressures, but Visa's robust cash flow and profitability support long-term growth potential for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT

About Visa Inc

Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.

Read more on V